Mark and David Geier Research

vaccine_syringeMark Geier’s first groundbreaking research occurred in 1971 when, alongside colleagues Dr. Carl Merril and Dr. John Petricciani, he discovered that when friendly viruses are introduced with genes for specific hereditary defects, they can in fact correct these existing defects. This discovery opened up numerous doors in the field of genetics, and was the catalyst for Dr. Geier’s storied career in research. After this initial widely-acclaimed publication, Dr. Geier continued to work with viruses and genes, submitting a dissertation on the effects of prokaryotic genes in eukaryotic cells, and soon after exploring the fate of bacterial viruses in contaminated vaccines. The subject of vaccines intrigued Dr. Geier, and he would later conduct even more significant vaccine research in the eighties and nineties by evaluating the effects of the pertussis vaccination and later, by specifically focusing on a possible connection between Thimerosal and childhood neurodevelopmental disorders like autism.

David Geier began his professional scientific career in the late 1990s, publishing numerous articles alongside his father on topics like hepatitis B vaccination and autoimmunity, pertussis vaccination and serious neurological injury, the relationship between influenza vaccinations and Guillian Barre Syndrome, and many others. David Geier’s most recent research focuses on the question of whether or not autism spectrum disorder and attention deficit disorders can be considered continuums.